Somatostatinoma: the decisions you may face

Cancer page →Second-opinion finder →

1 treatment setting, 1 with more than one named option. Each section lays out the options the standard of care names, what each is for, the trials behind them with their recorded results, the side effects and cautions on record, and questions to ask. Built from the cancer page's standard-of-care rows; nothing here is advice for your case.

Other settings

All cases

3 optionsCompare side by side →

Resection by size and site; the parent page's pathways for metastatic disease; screening of NF1 patients for other tumours.

The options, in plain words

EverolimusApprovedSmall-molecule mTOR inhibitor

An mTOR-blocking pill that doubled progression-free time with exemestane in 2012 and is now paired with the oral SERD giredestrant.

SunitinibApprovedSmall-molecule multi-kinase inhibitor (VEGFR, PDGFR, KIT)

Sunitinib is an anti-angiogenic pill approved for pancreatic neuroendocrine tumours, kidney cancer and GIST.

Peptide receptor radionuclide therapy (PRRT)Approved

A radioactive version of the hormone mimic used for the scan; it homes to neuroendocrine tumour cells and irradiates them from inside.

Systemic, receptor-targeted
Response and quality-of-life benefit
Imaging selects and monitors

Also referenced:Pancreatic neuroendocrine tumours

The evidence behind it

No trial record is attached to this row yet. The trials tab lists what is recruiting and the landmark trials for this cancer.

The main trade-offs on record

Everolimus all recorded rates →

Avoid grapefruit. Live vaccines are contraindicated.
7.5 mg (mild), 5 mg (moderate), 2.5 mg (severe).

Sunitinib all recorded rates →

Avoid grapefruit.
Known QT prolongation. Avoid other QT-prolonging drugs where possible; check ECG and correct potassium and magnesium before and during treatment.

Peptide receptor radionuclide therapy (PRRT)

Myelosuppression, rare MDS/AML (~2-3%)
Renal dose
Not curative; retreatment data limited

Questions to ask about this decision

Between Everolimus, Sunitinib and Peptide receptor radionuclide therapy (PRRT), which do you recommend for me, and what about my case would make you choose differently?
Why: Guidelines list several reasonable options; the choice turns on details of your tumour, your health and your priorities.
What is each option trying to achieve: cure, long control, or relief of symptoms, and over what time?
Why: The aim shapes how much side effect and disruption is worth accepting.
What happens if I delay, or decline this step for now? Is the decision reversible?
Why: Some decisions can wait for a second opinion or a trial slot; others cannot. Knowing which is part of the choice.
For my situation (all cases), which of the standard options do you recommend and why?
Why: Guideline options include: Resection by size and site; the parent page's pathways for metastatic disease; screening of NF1 patients for other tumours.
Am I a candidate for Everolimus, Sunitinib, and what side effects should I expect?
Why: Knowing the expected toxicities helps you plan work, family, and supportive care.

Add these to your appointment list, or take the full question set for this cancer.

How to read this page. Options and results come from OnCo records with their sources; the settings are the standard-of-care rows on the cancer page, and the lines of therapy are on the sequencing grid. Where a setting names one path, the choice is usually about timing, trials and where to be treated: see expert centres. OnCo is orientation, not medical advice.

Living with cancer·Standard of care